




MitoPathways at the Q-junction: mouse skeletal muscle fibres.

O2k-Workshop Report, IOC39,
Schroegen, Austria.

Gnaiger E

Oroboros Instruments Corp
High-Resolution FluoRespirometry
Schöpfstr 18, A-6020 Innsbruck, Austria
erich.gnaiger@orooboros.at; www.orooboros.at




Section		Page
	1. The SUIT protocol.....	1
	2. Limitations of the SUIT protocol	3
	3. References	3

[High-Resolution FluoRespirometry](#) with a [SUIT protocol](#)¹ for [OXPHOS](#) analysis² is presented as supplementary **T-issue** ([Oroboros](#) T-shirt).



1. The SUIT protocol

[Pyruvate&glutamate&malate](#) (PGM) were used in combination to induce N-linked [LEAK respiration](#) in permeabilized mouse skeletal muscle ([IOC39](#); Fig. O2).^{3,4} Saturating [ADP](#) (D; 2.5 mM final concentration) stimulated respiration to the level of [OXPHOS capacity](#) (*P* state), with a small effect of 10 μM [cytochrome c](#) (c), expressed as the [cytochrome c control factor](#) ($FCF_c < 0.01$; indicating integrity of the mt-outer membrane, mtOM). Without correction for residual oxygen consumption (ROX), the biochemical coupling efficiency, $(P-L)/P$, was 0.68 (RCR=3.1). Addition of [succinate](#) (S) stimulated respiration by convergent e-input through the [Q-junction](#). The corresponding succinate control factor was $(NS-N)/NS=0.47$, i.e., succinate increased respiration by 47%. NS-OXPHOS capacity was not stimulated further by [uncoupler](#) titration (U). Therefore, the capacity of the [phosphorylation system](#) matched the [ET-capacity](#) (*E* state). At $E=P$ the [E-P coupling control factor](#) is zero, indicating that there is no ET excess capacity over *P*, in striking contrast to human skeletal and cardiac muscle mitochondria.^{1,5,6} Inhibition of CI by [rotenone](#) (Rot) inhibited respiration to the level of S-linked ET-capacity. The corresponding N-control factor is $(NS-S)/NS=0.25$. S- was higher than N-linked respiratory capacity ($E=P$). NS-linked respiratory capacity was higher than respiration with any single e-input substrate state, indicating an additive effect at the Q-junction. However, since $NS < N+S$, the additive effect was incomplete, which indicates that any electron channelling through [supercomplexes](#) to

CIV was incomplete. Addition of [azide](#) (Azd; 10 mM) inhibited respiration to the level of [residual oxygen consumption](#) (ROX). ROX was 0.18 of NS-linked ET-capacity.



OXPHOS capacity: saturating [ADP]



www.bioblast/index.php/OXPHOS_capacity

2. Limitations of the SUIT protocol

2.1. Maximum OXPHOS- and ET-capacity

Evaluation of maximum respiratory capacities requires titration of further substrates activating additional [respiratory complexes](#) at the Q-junction ([CETF](#) and [CGpDH](#)).

2.2. Malate concentration

The [malate](#) concentration was 2 mM, to saturate N-linked respiration. However, at 2 mM malate, the fumarate concentration is increased to a level which inhibits succinate dehydrogenase. Then NS- and S-linked respiratory capacities are underestimated. A malate concentration of 0.5 mM, which saturates N-linked respiration and inhibits S-linked respiration to a lesser extent, represents an improved standard. » [Optimum malate concentration in SUIT protocols](#)

2.3. ROX correction

The fact that ROX was higher in the NS substrate state compared to N-linked LEAK respiration indicates that ROX is partially controlled by the substrate state. Therefore, a single measurement of ROX cannot be applied for correction of total oxygen consumption in the different substrate states. Total respiration, therefore, represents apparent coupling states L' , P' and E' (Fig. 1). ROX correction is possible in the present experiment only for NS- and S-linked respiration. [Azide](#) inhibits not only CIV but other heme-based oxidases and peroxidases, and therefore may interfere with ROX beyond blocking respiratory electron transfer. Based on this argument, a combination of CII- and CIII-inhibitors (malonic acid, antimycin A, myxothiazol) may yield more consistent results, although any ROS scavenged by cytochrome c may in the absence of a CIV-inhibitor result in respiratory oxygen consumption through CIV.

3. References

1. Doerrier C, Garcia-Souza LF, Krumschnabel G, Wohlfarter Y, Mészáros AT, Gnaiger E (2018) High-Resolution FluoRespirometry and OXPHOS protocols for human cells, permeabilized fibers from small biopsies of muscle, and isolated mitochondria. *Methods Mol Biol* 1782:31-70. - [»Bioblast Access](#)
 2. Gnaiger E (2014) Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 4th ed. *Mitochondr Physiol Network* 19.12. Oroboros MiPNet Publications, Innsbruck: 80 pp. [»Open Access](#)
 3. Oroboros IOC39. International course on high-resolution respirometry. Schroecken 13-17 April 2007. *Mitochondr Physiol Network* 12.14: 1-8. [»Open Access](#) - O2k-Demo experiment 2007-04-14 A-03 carried out by [Hélène Lemieux](#) at [IOC39](#), Schröcken.
 4. Oroboros (2014) Oxygraph-2k manual titrations: SUIT protocols with mitochondrial preparations. *Mitochondr Physiol Network* 09.12(11): 1. - [»Open Access](#)
 5. Gnaiger E (2009) Capacity of oxidative phosphorylation in human skeletal muscle. New perspectives of mitochondrial physiology. *Int J Biochem Cell Biol* 41: 1837-1845. - [»PMID: 19467914](#)
 6. Lemieux H, Semsroth S, Antretter H, Höfer D, Gnaiger E (2011) Mitochondrial respiratory control and early defects of oxidative phosphorylation in the failing human heart. *Int J Biochem Cell Biol* 43: 1729-38. - [»Bioblast Access](#)
- » Product: [Oroboros Oxygraph-2k](#), [O2k-Catalogue](#)